TVRD on Nasdaq

Tvardi Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Whitehawk Therapeutics, Inc., Ovid Therapeutics Inc. or Immunome Inc., or pick any stock.

  • TickerTVRD on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSugar Land, Texas1
  • Incorporated inDE2
  • Business address3 Sugar Creek Ctr. Blvd., Ste 525, Sugar Land, Tx 774782
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need. Based upon our founders ’ seminal work and deep understanding of the transcription factor STAT3, we have designed an innovative approach to directly inhibit STAT3, a highly validated, yet historically undruggable target. Leveraging this expertise, we are developing a pipeline of STAT3 inhibitors with a differentiated mechanism of action and convenient oral dosing.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-393.8%Operating margin4
-411.9%Net margin4
-66.0%Revenue growth, 20245
-$19.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development100¢$23.6M

Out of $7.1M in revenue.54 The company lost money this year.

Financial statements

Revenue6785$7.1M in 2024−64% since 2019
0$50.0M$100.0M$150.0M2019: $19.9M$19.9M20192020: $135.1M$135.1M2020+579%2021: $23.0M$23.0M2021−83%2022: $41.9M$41.9M2022+82%2023: $21.0M$21.0M2023−50%2024: $7.1M$7.1M2024−66%
Operating income67854-$28.1M in 2024−75% since 2019
-$150.0M-$100.0M-$50.0M0$50.0M2019: -$111.7M-$111.7M20192020: $5.4M$5.4M20202021: -$89.1M-$89.1M20212022: -$87.5M-$87.5M2022−2%2023: -$121.5M-$121.5M2023+39%2024: -$28.1M-$28.1M2024−77%
Net income67854-$29.4M in 2024−72% since 2019
-$150.0M-$100.0M-$50.0M0$50.0M2019: -$106.4M-$106.4M20192020: $8.4M$8.4M20202021: -$88.4M-$88.4M20212022: -$85.5M-$85.5M2022−3%2023: -$118.5M-$118.5M2023+39%2024: -$29.4M-$29.4M2024−75%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Research and development$18.0M$23.6M
General and administrative$8.7M$4.5M
Total operating expenses$26.7M$28.1M
Loss from operations-$26.7M-$28.1M
Interest income$1.4M$747.0K
Other income (expense), net$7.2M-$2.0M
Net loss per share attributable to common stockholders, Basic (in dollars per share)-$2.46-$11.42
Net loss per share attributable to common stockholders, Diluted (in dollars per share)-$3.26-$11.42
Weighted-average common shares outstanding, Basic (in shares)7.4M shares2.6M shares
Weighted-average common shares outstanding, Diluted (in shares)7.8M shares2.6M shares
Net loss-$18.2M-$29.4M
Unrealized gain on short-term investments$8.0K
Comprehensive loss-$18.2M-$29.4M

Compare Tvardi Therapeutics, Inc. with another company

Leadership

Who has led Tvardi Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Derek T. Chalmers2014–2021
  2. Christopher Posner2022–2025
  3. Imran Nizamudin Alibhai2025–now

President

  1. Derek T. Chalmers2014–2021
  2. Christopher Posner2022–now

Chief financial officer

  1. Josef Schoell2014–2017
  2. Mani Mohindru2017–2019
  3. Thomas Charles Reilly2020–2022
  4. Ryan D. Maynard2022–2024
  5. Avi Daniel Conn2025–now
201520202025
Board members and other officers (26)

Former names

  • Cara Therapeutics, Inc.Oct 4, 2013 to Apr 11, 20252
  • Cara Therapeutics IncDec 6, 2005 to Jul 21, 20102

Timeline

  1. Apr 17, 2025New chief executive Imran Nizamudin Alibhai becomes CEO12
  2. Mar 1, 2022New chief executive Christopher Posner becomes CEO13
  3. Jan 30, 2014New chief executive Derek T. Chalmers becomes CEO14

Filings

316 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 69 major events, 142 insider forms, 27 large holders, 58 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. Aug 14, 20268-K EDGAR
  3. Jul 30, 20268-K EDGAR
  4. Jul 17, 20268-K EDGAR
  5. Jul 17, 2026424B5 EDGAR
  6. Jul 7, 20268-K EDGAR
  7. Jun 11, 20264 EDGAR
  8. Jun 11, 20264 EDGAR
  9. Jun 11, 20264 EDGAR
  10. Jun 11, 20264 EDGAR
  11. Jun 11, 20264 EDGAR
  12. Jun 11, 20268-K EDGAR
  13. May 13, 2026EFFECT EDGAR
  14. May 12, 2026EFFECT EDGAR
  15. May 8, 2026POS AM EDGAR
  16. May 8, 2026CORRESP EDGAR
  17. May 8, 202610-Q EDGAR
  18. May 8, 20268-K EDGAR
  19. May 7, 2026UPLOAD EDGAR
  20. May 1, 2026S-3 EDGAR

The 316 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

52 open-market trades by officers, directors and large owners since October 2021: 0 buys and 52 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 28, 2025Posner ChristopherPRESIDENT AND CEOSale583$4.75$2.8KForm 4
Feb 28, 2025Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Sale163$4.76$776Form 4
Feb 4, 2025Posner ChristopherPRESIDENT AND CEOSale372$4.72$1.8KForm 4
Nov 4, 2024Posner ChristopherPRESIDENT AND CEOSale3,668$0.29$1.1KForm 4
Aug 1, 2024Posner ChristopherPRESIDENT AND CEOSale4,149$0.35$1.5KForm 4
May 2, 2024Posner ChristopherPRESIDENT AND CEOSale3,936$0.75$3.0KForm 4
Apr 5, 2024Goncalves JoanaCHIEF MEDICAL OFFICERSale2,753$0.83$2.3KForm 4
Apr 5, 2024Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Sale2,753$0.83$2.3KForm 4
Feb 29, 2024Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Sale3,293$0.89$2.9KForm 4
Feb 29, 2024Posner ChristopherPRESIDENT AND CEOSale5,834$0.89$5.2KForm 4
Feb 29, 2024Goncalves JoanaCHIEF MEDICAL OFFICERSale3,293$0.89$2.9KForm 4
Feb 8, 2024Posner ChristopherPRESIDENT AND CEOSale35,575$0.53$18.9KForm 4
Feb 1, 2024Posner ChristopherPRESIDENT AND CEOSale4,981$0.55$2.7KForm 4
Nov 2, 2023Posner ChristopherPRESIDENT AND CEOSale3,796$1.22$4.6KForm 4
Aug 3, 2023Posner ChristopherPRESIDENT AND CEOSale4,307$3.07$13.2KForm 4
Jun 23, 2023Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Sale2,483$3.51$8.7KForm 4
Jun 23, 2023Menzaghi Frederique Ph.D.CHIEF SCIENTIFIC OFF,SVP-R&DSale2,993$3.51$10.5KForm 4
Jun 23, 2023Goncalves JoanaCHIEF MEDICAL OFFICERSale2,723$3.51$9.6KForm 4
May 5, 2023Posner ChristopherPRESIDENT AND CEOSale3,869$4.40$17.0KForm 4
Apr 4, 2023Terrillion ScottSEC'Y; CHIEF COMPLIANCE & G.C.Sale2,481$4.91$12.2KForm 4

All 52 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 58. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Slate Path Capital LP704,118$1.3M0.0%No change
Vanguard Capital Management LLC344,382$654.3K0.0%−326
American Financial Group Inc223,659$425.0K0.1%No change
UBS Group AG111,133$211.2K0.0%+60,679
Silvercrest Asset Management Group LLC101,034$192.0K0.0%No change
BlackRock, Inc.95,478$181.4K0.0%−292,597
Renaissance Technologies LLC91,409$173.7K0.0%−691
Geode Capital Management, LLC90,350$171.7K0.0%−91,989
Morgan Stanley77,845$147.9K0.0%+4,951
Duncan Williams Asset Management, LLC63,241$120.2K0.0%No change
Vanguard Fiduciary Trust Co44,710$84.9K0.0%−2,162
Russell Investments Group, Ltd.43,228$82.1K0.0%+19,921
State Street Corp33,900$64.4K0.0%−63,331
Susquehanna International Group, Llp33,165$63.0K0.0%New
Aqr Capital Management LLC27,096$51.5K0.0%−15,096
Savant Capital, LLC19,462$49.4K0.0%New
Northern Trust Corp21,836$41.5K0.0%−27,245
Diadema Partners LP16,607$31.6K0.0%New
XTX Topco Ltd14,868$28.2K0.0%New
Brown Advisory Inc11,200$21.3K0.0%New
Arax Advisory Partners11,003$20.9K0.0%+2,670
Qube Research & Technologies Ltd10,210$19.4K0.0%New
Persistent Asset Partners Ltd4,253$8.1K0.0%New
PNC Financial Services Group, Inc.3,518$6.7K0.0%+2,999
Vanguard Global Advisers, LLC3,400$6.5K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54